[1]
Alzforum newsletter March 25, 2019: https://www.alzforum.org/news/research-news/biogeneisai-halt-phase-3-aducanumab-trials
[2]
Hsu D, Marshall GA. Primary and secondary prevention trials in Alzheimer disease: looking back, moving forward. Curr Alzheimer Res 14(4): 426-40. (2017).
[3]
Maloney B, Lahiri DK. Epigenetics of dementia: understanding the disease as a transformation rather than a state. Lancet Neurol 15(7): 760-74. (2016).
[4]
Weinstein G, Preis SR, Beiser AS, Kaess B, Chen TC, Satizabal C, et al. Clinical and environmental correlates of serum BDNF: A descriptive study with plausible implications for AD research. Curr Alzheimer Res 14(7): 722-30. (2017).
[5]
Lauritzen I, Pardossi-Piquard R, Bourgeois A, Bécot A, Checler F. Does intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein trigger early neurotoxicity in Alzheimer’s disease? Curr Alzheimer Res (2019).
[http://dx.doi.org/10.2174/1567205016666190325092841]
[http://dx.doi.org/10.2174/1567205016666190325092841]
Current Alzheimer Research
Title:Lessons from Alzheimer's Disease (AD) Clinical Trials: Instead of “A-Drug”, AD-D prevention to Avert AD
Volume: 16 Issue: 4
Author(s): Debomoy K. Lahiri
Affiliation:
Export Options
About this article
Cite this article as:
Lahiri K. Debomoy , Lessons from Alzheimer's Disease (AD) Clinical Trials: Instead of “A-Drug”, AD-D prevention to Avert AD, Current Alzheimer Research 2019; 16 (4) . https://dx.doi.org/10.2174/156720501604190424114752
DOI https://dx.doi.org/10.2174/156720501604190424114752 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
38
7
1
1
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Target Identification Technologies for the Personalised Therapy of Type II Diabetes and Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Snake Venom Peptides and Low Mass Proteins: Molecular Tools and Therapeutic Agents
Current Medicinal Chemistry Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Nonalcoholic fatty liver disease in children and adolescents – Relationship with Polycystic Ovary Syndrome
Current Pharmaceutical Design Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds
Current Pharmaceutical Design Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Antioxidant Treatment and Endothelial Dysfunction: Is it Time for Flavonoids?
Recent Patents on Cardiovascular Drug Discovery Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Basic Mechanisms in Atherosclerosis: The Role of Calcium
Medicinal Chemistry Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Decorin Biology, Expression, Function and Therapy in the Cornea
Current Molecular Medicine Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design